Philip Morris International (PMI) has concluded its controversial £1.1bn takeover of UK health firm Vectura, becoming its majority shareholder, along with that of the Danish oral-products manufacturer Fertin Pharma.

Confirming the completion of the deal today, Vectura, which develops and manufactures inhalers, said that the offer from the Big Tobacco company £1.65 per share – now becomes “unconditional in all respects”, meaning the remaining stakeholders cannot prevent it.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

Shop reports

Request a free sample of this report:

“ Healthy business? PMI completes its takeover of Vectura and Fertin Pharma ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ Healthy business? PMI completes its takeover of Vectura and Fertin Pharma ”






      Philip Morris International (PMI) has concluded its controversial £1.1bn takeover of UK health firm Vectura, becoming its majority shareholder, along with that of the Danish oral-products manufacturer Fertin Pharma.

      Confirming the completion of the deal today, Vectura, which develops and manufactures inhalers, said that the offer from the Big Tobacco company £1.65 per share – now becomes “unconditional in all respects”, meaning the remaining stakeholders cannot prevent it.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik